Experimental Study On Nasal Mucosal Administration Of Type ¢ò Collagen Allosteric Peptide In The Treatment Of Collagen-Induced Arthritis
Keywords
Arthritis, Experimental, Allosteric Peptide, Collagen Type ¢ò
Abstract
Objective: To study the inhibition of collagen-induced arthritis (cia) by nasal mucosal administration of an allosteric peptide that replaces amino acids 267, 270, and 271 in the 263-272 sequence of type ¢¢ collagen (collagen ¢¢, c¢¢) with alanine. Effect and mechanism of action. Method: immunize Lewis rats with bovine c¢¢ to induce cia. On the day of onset, intranasal instillation treatment of c¢¢ allosteric peptide and prototype peptide was started. The administration was continued every day. After 5 days, administration was changed to every other day. , the blank control group was given phosphate buffered solution (PBS). Joint swelling was observed, and arthritis scores and weight changes were recorded. After the treatment, the rats were sacrificed, and pathological sections of the posterior ankle joints were performed to observe joint pathological changes. elisa method The changes in serum anti-c¢¢ antibody subtypes and cytokines were detected, flow cytometry was used to detect changes in peripheral blood CD4+CD25+T cells, and fluorescence quantitative PCR was used to detect the expression levels of foxp3 and tgf-¦ÂmRNA in the spleen and lymph nodes. Results: ( 1) c¢¢ allosteric peptide can inhibit the development of cia. At the end of the experiment, the arthritis scores of rats in the c¢¢ allosteric peptide, prototype peptide and PBS groups were 2.50¡À2.43, 4.50¡À2.23 and 6.33¡À2.73 respectively (allosteric peptide treatment group and Compared with the PBS control group, p<0.05), the pathological scores of the posterior ankle joints of rats in each group were 1.33¡À1.07, 2.17¡À0.94 and 2.83¡À0.58 respectively. Compared with the PBS control group, the cII allosteric peptide can significantly inhibit the CIA joint. Development of lesions (p<0.05). (2) Compared with PBS control group, cII allosteric peptide can reduce the titer of anti-cII antibody IgG2a isoform in cia rats (0.56¡À0.19 and 0.95¡À0.29, p<0.05 ). The levels of gamma interferon (interferon-¦Ã, ifn-¦Ã) in the serum of rats in the c¢¢ allosteric peptide, prototype peptide and PBS control group were (185.33¡À29.77), (231.62¡À41.82) and (220.64¡À83.61) ng respectively. /l, compared with the prototype peptide group, c¢¢ allosteric peptide can reduce the level of ifn-¦Ã in rat serum. (3) Effect of c¢¢ allosteric peptide treatment on regulatory T cells: peripheral blood cim+cd25 of rats in 3 groups There is no statistical significance in the proportion of +T cells to CD4+T cells. The expression levels of foxp3 and transforming growth factor b (transforming growth factors ¦Â, tgf-¦Â) mRNA in the spleen and lymph nodes of rats in the c¢¢ allosteric peptide treatment group were higher than those in the control group. trend, but the difference is not statistically significant. Conclusion: Nasal mucosal administration of c¢¢ allosteric peptide can inhibit the development of cia. The c¢¢ allosteric peptide may mainly inhibit the production of IgG2a type anti-c¢¢ antibodies in cia rats and reduce serum levels. ifn-¢¢, thereby inhibiting th1 type immune response and exerting a therapeutic effect. For further information of this article and research, feel free to contact our team for asssitance. Original research was done by Zhao Jinxia, Li Ru, He Jing, Shi Jinxia, Li Zhanguo
About ETChem
ETChem, a reputable Chinese Collagen factory manufacturer and supplier, is renowned for producing, stocking, exporting, and delivering the highest quality collagens. They include marine collagen, fish collagen, bovine collagen, chicken collagen, type I collagen, type II collagen and type III collagen etc. Their offerings, characterized by a neutral taste, and instant solubility attributes, cater to a diverse range of industries. They serve nutraceutical, pharmaceutical, cosmeceutical, veterinary, as well as food and beverage finished product distributors, traders, and manufacturers across Europe, USA, Canada, Australia, Thailand, Japan, Korea, Brazil, and Chile, among others.
ETChem specialization includes exporting and delivering tailor-made collagen powder and finished collagen nutritional supplements. Their extensive product range covers sectors like Food and Beverage, Sports Nutrition, Weight Management, Dietary Supplements, Health and Wellness Products, ensuring comprehensive solutions to meet all your protein needs.
As a trusted company by leading global food and beverage brands and Fortune 500 companies, ETChem reinforces China’s reputation in the global arena. For more information or to sample their products, please contact them and email karen(at)et-chem.com today.
